{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-26-000045","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2026-06-11T11:16:14+00:00","discovered_at":"2026-06-11T11:20:00.249020+00:00","generated_at":"2026-06-11T11:20:34.162172+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xeris Biopharma exchanges ~69% of 8% Convertible Notes due 2028 for cash and stock","bullets":["Entered private exchange to retire ~$23M (69%) of 8% Convertible Senior Notes due 2028.","Exchange consideration: $23M cash plus shares based on 21-day VWAP; ~4.6M shares if price is $6.71.","After exchange, $10.5M notes remain outstanding; annual interest savings ~$2M.","Expected close around July 15, 2026; Morgan Stanley acted as placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-26-000045","json":"https://secwatch.observer/filing/0001867096-26-000045.json","markdown":"https://secwatch.observer/filing/0001867096-26-000045.md","text":"https://secwatch.observer/filing/0001867096-26-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/0001867096-26-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/xers-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:20:34.162172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"afd6c2bb2c6cfb4d9528abcd2be348f05eddc4bb","claim":"Xeris Biopharma Holdings, Inc. issued common stock to certain holders (the \"Noteholders\") of its 8.00% Convertible Senior Notes due 2028 for approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company's common stock.","evidence_excerpt":"On June 10, 2026, Xeris Biopharma Holdings, Inc. (the “Company”) entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders (the “Noteholders”) of its 8.00% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which the Noteholders have agreed to exchange (the “Exchange”) approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company’s common stock (the “Exchange Consideration”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709626000045/0001867096-26-000045-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Purchaser","value":"certain holders (the \"Noteholders\") of its 8.00% Convertible Senior Notes due 2028"},{"label":"Consideration","value":"approximately $23 million in aggregate principal amount of the outstanding 2028 Notes for a combination of cash and shares of the Company's common stock"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}